Last reviewed · How we verify
NCT04452630
Cardiovascular Consequences After COVID-19
trial testing Infectious Disease and Cardiology Clinical Consultations in Cardiovascular Consequences After an Episode of COVID 19 in 80 participants. Terminated before completion.
1 February 2023
Quick facts
| Lead sponsor | Assistance Publique Hopitaux De Marseille |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 23 June 2020 |
| Primary completion | 1 February 2023 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Infectious Disease and Cardiology Clinical Consultations
Conditions studied
- Cardiovascular Consequences After an Episode of COVID 19 — all drugs for Cardiovascular Consequences After an Episode of COVID 19 →
Sponsor
Assistance Publique Hopitaux De Marseille — full company profile →
Who can join
18 and older, any sex, with Cardiovascular Consequences After an Episode of COVID 19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The occurrence of cardiovascular complications in SARS-CoV-2 infections appears to be more frequent than in other viral respiratory infections, probably due to a singular pathophysiology of this coronavirus. The lack of characterization of cardiovascular damages linked to Covid-19 could have medium and long-term consequences on the prognosis of patients. This problematic could lead to a second major public health problem linked to Covid-19 and it is therefore crucial to keep monitoring and screening patients at risk. In this context of emerging infectious diseases, of poorly characterized cardiovascular damages during infection and of absence of data on the long-term evolution of the infection, the investigators propose to carry out a prospective and observational cohort study focused on the evaluation and the systematic cardiovascular follow up of patients who survived an episode of Covid-19, regardless of their cardiovascular profiles.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long-term cardio-vascular risk assessment in chronic kidney disease and kidney transplanted patients following SARS-COV-2 disease: protocol for multi-center observational match controlled trial.
Tapoi L, Apetrii M, Dodi G, Nistor I, et al · · 2022 · cited 2× · PMID 35524223 · DOI 10.1186/s12882-022-02809-4 -
Long-term Cardio-vascular Risk Assessment in Chronic Kidney Disease and Kidney Transplanted Patients Following SARS-COV-2 Disease: Protocol for Multi-center Observational Match Controlled Trial
Tapoi L, Apetrii M, Dodi G, Nistor I, et al · · 2022 · DOI 10.21203/rs.3.rs-1236020/v1
Verify or expand the search:
- PubMed search for NCT04452630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assistance Publique Hopitaux De Marseille trials
Trials by the same sponsor.
- NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
- NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
- NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
- NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
- NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04452630 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04452630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing